OCEANSIDE, CA--(Marketwire - Jan 24, 2013) - Therapeutic Solutions International, Inc. (OTCQB: TSOI) announced today the signing of an agreement with Smile Cosmetic SARL for the distribution of Therapeutic Solutions International's AMPSA products in Morocco.

"This sales agreement with Smile Cosmetic SARL marks a significant geographic expansion for TSI's product distribution," stated Tim Dixon, CEO of Therapeutic Solutions International, Inc. "With distribution in Morocco, we have entered the North African market."

Mustapha Guessous, General Manager of Smile Cosmetic, said, "We are very happy to sign this new distribution contract with TSI and to represent Migran-X® products in Morocco. We consider that this will be a great opportunity for us and our customers."

Mr. Guessous added, "Smile Cosmetic firmly believes that there is a great potential and a large market for the Migran-X® products in Morocco and we hope to develop a great partnership with TSI and earn the opportunity in the future to represent this company in the whole of North Africa."

About Smile Cosmetic SARL

Smile Cosmetic SARL is a company founded by two sisters, Dr. Amal Bennis and Dr. Loubna Bennis, and their General Manager Mr. Mustapha Guessous. Headquartered in Casablanca, Morocco, Smile Cosmetic and its strong sales team specialize in the distribution and commercialization of innovative products to dentists as well as the general public.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is a global manufacturer of the chairside anterior midpoint stop appliance (AMPSA) devices marketed internationally under the trade names Migran-X® and AMPSA CS®, which have helped countless patients prevent debilitating migraine and tension headache pain, bruxism, clenching, grinding, and TMJ disorders. The Migran-X® and AMPSA CS® devices are the most effective non-drug US FDA cleared dental method of migraine prevention on the market today. Dentists fit the AMPSA devices on patients for the treatment of medically diagnosed migraine pain, as well as migraine associated tension-type headaches, in order to reduce their migraine signs and symptoms through the reduction of trigeminally innervated muscular activity, and to prevent bruxism and TMJ syndrome through the reduction of trigeminally innervated muscular activity. In clinical trials reviewed by the US FDA, 82% of medically diagnosed migraine sufferers using the Migran-X device averaged a 77% average reduction of migraine events in the first eight weeks of use. Successful outcomes are produced by reducing head, neck and jaw muscle contraction intensity by nearly 70%. Therapeutic Solutions International also licenses laboratories to manufacture and sell semi-custom AMPSA devices internationally. The Company is also a provider of continuing education programs in the United States focused on AMPSA devices. The Company does not sell AMPSA products in the United States. The Company's corporate website is www.therapeuticsolutionsint.com. Non-US dentists and physicians can order our AMPSA products at www.ordertsoi.com.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to the need for further financing, our exit from the US market for AMPSA products in 2013, the need to procure additional international distributors, direct competition beginning in 2013, reliance on key personnel, possible introduction of new product lines, and other specific risks set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at www.sec.gov.

Contact Information:

For more information please contact:
Jens Dalsgaard
Constellation Asset Advisors, Inc
(415) 524-8500